Reporting in Nature, Gray and colleagues identify and characterize a selective allosteric inhibitor of BCR–ABL, GNF-5, that cooperates with ATP competitive inhibitors to inhibit both wild-type ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.

Numerous clinical trials of combination treatments using checkpoint inhibitors are now underway as pharmaceutical companies seek ways to improve the response rates. One way in which ABL Bio is ...

Uliledlimab (TJ004309) is an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. I-Mab owns worldwide rights to ...

Enliven's initial phase 1 data for ELVN-001 in CML shows promising tolerability and activity in heavily pretreated patients. But read why ELVN stock is a Sell.

Enliven Therapeutics' ELVN-001 shows promising results for CML patients. Click here to read what makes ELVN stock a ...